MERIDIAN DIAGNOSTICS INC
10-Q/A, EX-99, 2000-09-08
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: MERIDIAN DIAGNOSTICS INC, 10-Q/A, 2000-09-08
Next: PRIMARY TREND FUND INC, 24F-2NT, 2000-09-08






                                                                     EXHIBIT 99

                           FORWARD LOOKING STATEMENTS

The Private Securities Litigation Reform Act of 1995 provides a safe harbor from
civil  litigation  for  forward-looking  statements  accompanied  by  meaningful
cautionary  statements.  These statements  identify important factors that could
cause actual  results to differ  materially  from those that might be projected.
Meridian's  continued growth depends,  in part, on its ability to introduce into
the  marketplace   enhancements  of  existing  products  or  new  products  that
incorporate  technological  advances,  meet customer requirements and respond to
products  developed  by  the  Company's  competition.   While  the  Company  has
introduced  over 35  internally-developed  products since 1991,  there can be no
assurance that it will be successful in the future in introducing  such products
on  a  timely  basis.  Ongoing  consolidations  of  reference  laboratories  and
formation of  multi-hospital  alliances may cause adverse changes to pricing and
distribution.  One of  Meridian's  main  growth  strategies  is  acquisition  of
companies  and  product  lines.  There  can  be  no  assurance  that  additional
acquisitions will be consummated or that, if consummated, will be successful and
the acquired businesses successfully integrated into Meridian's operations.



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission